Results

Total Results: 1,229 records

Showing results for "adverse event".
Users also searched for: patient safety indicators

41. Developing and Piloting a Tool To Create Dot Plots To Summarize Pooled Data for Multiple Outcomes in Systematic Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/dot-plots-methods.pdf
    October 01, 2021 - event; ALT = alanine transaminase; AST = aspartate aminotransferase; CI = confidence interval; Ctrl … event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CV = cardiovascular; MI = … event Note: For variable abbreviations, see Table 2A 6 Table 2B. … Advantages of visualisations to evaluate and communicate adverse event information in randomised … Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled

42. Evidence-based Practice Center Systematic Review Protocol: Depression in Children: Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/depression-childhood-protocol.pdf
    August 06, 2018 - effect*[Title/Abstract] OR adverse event*[Title/Abstract] OR adverse reaction*[Title/Abstract] OR Adverse … Effects"] or [mh /AE,CI,DE,MO,PO,TO] or adverse effect*:ti,ab or adverse event*:ti,ab or adverse … Effects" OR TX “adverse effect” or TX “adverse event” OR TX “adverse events” OR TX "adverse outcome … Effects"] or [mh /AE,CI,DE,MO,PO,TO] or adverse effect*:ti,ab or adverse event*:ti,ab or adverse … Effects" OR TX “adverse effect” or TX “adverse event” OR TX “adverse events” OR TX "adverse outcome

43. Developing and Piloting a Tool To Create Dot Plots To Summarize Pooled Data for Multiple Outcomes in Systematic Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/dot-plots-methods.pdf
    October 01, 2021 - event; ALT = alanine transaminase; AST = aspartate aminotransferase; CI = confidence interval; Ctrl … event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CV = cardiovascular; MI = … event Note: For variable abbreviations, see Table 2A 6 Table 2B. … Advantages of visualisations to evaluate and communicate adverse event information in randomised … Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled

44. Clinical-Care-Rapid-Review-Appendix-C (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/clinical-care-rapid-review-appendix-c.xlsx
    January 01, 2018 - is defined as an adverse event that involved communication by RM with the patient and family and/or … QI evaluates the adverse outcome to determine if system and/or individual provider error occurred. … ” When an adverse event occurs, risk management is alerted and support services for the involved clinician … When an adverse event occurs, an internal investigation follows, during which internal and external experts … The algorithms outline roles and actions to be taken after an adverse event meeting a threshold level

45. Cannabis-2022-Surv-Rep-3-Tables-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-tables-F1-4.xlsx
    January 01, 2022 - Any Adverse Event Intervention B, N of Any Adverse Event (Numerator) Intervention B, N Analyzed for … Any Adverse Event (Denominator) Intervention B, % With Any Adverse Event Intervention C, N of Any Adverse … Adverse Event (Denominator) Intervention D, % With Any Adverse Event Intervention A, N of Serious Adverse … % With Serious Adverse Event Intervention B, N of Serious Adverse Event (Numerator) Intervention B, … ) Intervention C, % With Serious Adverse Event Intervention D, N of Serious Adverse Event (Numerator)

46. Evidence Summary for Treatments for Acute Pain: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-evidence-summary.pdf
    December 01, 2020 - • Opioids are probably associated with increased risk of short-term adverse events versus nonopioid … pharmacologic therapy for acute pain, including any adverse event, study withdrawal due to adverse … events, nausea, dizziness, and somnolence, but serious adverse events are uncommon in randomized trials … Opioids were associated with increased risk of short-term adverse events (any adverse event, study withdrawal … due to adverse events, dizziness and nausea) for both comparisons.

47. Cer-250-Cannabis-Table-E5-2022-Update 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-table-e5-2022-update_0.xlsx
    January 01, 2022 - C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. NR, RR for A vs. … B 0.72 (95% CI 0.49 to 1.07) Serious adverse events: none in any group Withdrawals due to adverse events … B Total patients reporting treatment related adverse event: 21.1% (71/337) vs. 35.0% (118/337), RR 0.60 … B % (n/N) Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18) Serious … adverse events: 13% (28/215) vs. 19.4% (42/216), RR 0.67 (95% CI 0.43 to 1.04) Withdrawals due to adverse

48. Cannabis-2022-Surv-Rep-3-Table-F5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-table-F5.xlsx
    January 01, 2022 - C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. NR, RR for A vs. … B 0.72 (95% CI 0.49 to 1.07) Serious adverse events: none in any group Withdrawals due to adverse events … B Total patients reporting treatment related adverse event: 21.1% (71/337) vs. 35.0% (118/337), RR 0.60 … B % (n/N) Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18) Serious … adverse events: 13% (28/215) vs. 19.4% (42/216), RR 0.67 (95% CI 0.43 to 1.04) Withdrawals due to adverse

49. Cannabis-2022-Update-Surv-Rep-1-App-F-5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F-5.xlsx
    January 01, 2022 - C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. NR, RR for A vs. … B 0.72 (95% CI 0.49 to 1.07) Serious adverse events: none in any group Withdrawals due to adverse events … B Total patients reporting treatment related adverse event: 21.1% (71/337) vs. 35.0% (118/337), RR 0.60 … B % (n/N) Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18) Serious … adverse events: 13% (28/215) vs. 19.4% (42/216), RR 0.67 (95% CI 0.43 to 1.04) Withdrawals due to adverse

50. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
    March 01, 2013 - Overall adverse event profiles appeared to be similar for biologic DMARDs and placebo. … for at least 28 weeks. 78.2% had at least one adverse event (AE), but only 4.6% had a No safety … Legend: ACR: American College of Rheumatology; AE(s): Adverse Event(s); CER: Comparative Effectiveness … for at least 28 weeks. 78.2% had at least one adverse event (AE), but only 4.6% had a serious AE … Overall adverse event profiles appeared to be similar for biologic DMARDs and placebo.

51. Pharmacologic Management of Acute Pain by EMS in the Prehospital Setting Protocol Amendment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/acute-pain-ems-protocol-amendment.pdf
    January 28, 2019 - event (as in any subject that experienced an adverse event during the study period) • KQ2c: o … events as in the total number of subjects that experienced an adverse event b: English language abstracts … The original full publication will always be used as the primary data source in the event discrepant … for rare event outcome: a simulation study. … event (as in any subject that experienced an adverse event during the study period).

52. Kidney-Stone-Prevention Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_executive.pdf
    March 01, 2013 - trial reported results regarding the number of participants with at least one adverse event or with … event or with any specific adverse event.54 Decreased Soft Drink Intake • The single eligible RCT … • 24.5 percent of participants randomized to citrate had any adverse event versus none assigned to … event. … The two trials that reported specific adverse events reported no individual adverse event in more than

53. S5 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s5.pdf
    October 01, 2007 - events.13 The National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance … event, not by factors that influence the outcome, may be the better approach in using such simulations … Real-time vaccine safety surveillance for the early detection of adverse events. … Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Ad- verse Drug Event … A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length

54. Disposition of comments_Comparative Effectiveness Review No. 244: Safety of Vaccines Used for Routine Immunization in the United States: An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-244-safety-of-vaccines.pdf
    May 25, 2021 - We agree that the timing of each adverse event relates to the vaccine and particular adverse event. … However, such detail at a study level or even vaccine/adverse event level would make the report even … event. … event. … adverse event) is missing.

55. App-D-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
    September 30, 2015 - Abbreviations: AE = adverse event; BMI = body mass index; CI = confidence interval; COWS = Clinical Opiate … event; SD = standard deviation; SE = standard error; SR = slow release; TENS = transcutaneous electrical … D Any opioid-related event: 5.3% vs. 6.1% vs. 3.4% vs. 3.6%, p<0.0001 Suicide (fatal or nonfatal): 1.0% … HR 1.67 (95% CI 1.51 to 1.84) Safety event hospitalizations A vs. B vs. … event B: Controls: (n=2,311), patients without an opioid-related adverse event, 1:1 matching based on

56. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain_executive.pdf
    October 01, 2011 - to 0.56) compared to nonselective NSAIDs, but the difference in risk of any adverse event or withdrawal … due to any adverse event did not reach statistical significance). … Meloxicam was also associated with decreased risk of any adverse event (RR 0.91, 95% CI 0.84 to 0.99) … event. … Etodolac was associated with lower risk of any adverse event compared to nonselective NSAIDs (RR 0.83

57. Appendix-E-Table-E5 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5_0.xlsx
    May 29, 2025 - Outcomes Quality of Life Outcomes Anxiety and Depression Outcomes Sleep Outcomes Opioid Use Outcomes Adverse … C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. … NR Serious adverse events: none in any group Withdrawals due to adverse events 6 months: 10% (5/49) vs … B % (n/N) Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18) Serious … adverse events: 13% (28/215) vs. 19.4% (42/216), OR 0.64 (95% CI 0.38 to 1.04) Withdrawals due to adverse

58. Cannabis-App-F5-Table-Surveillance-Report-2 0 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0_0.xlsx
    May 29, 2025 - Outcomes Quality of Life Outcomes Anxiety and Depression Outcomes Sleep Outcomes Opioid Use Outcomes Adverse … C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. … NR Serious adverse events: none in any group Withdrawals due to adverse events 6 months: 10% (5/49) vs … B % (n/N) Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18) Serious … adverse events: 13% (28/215) vs. 19.4% (42/216), OR 0.64 (95% CI 0.38 to 1.04) Withdrawals due to adverse

59. Cannabis-2023-Surv-Rep-1-App-F (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
    January 01, 2023 - Any Adverse Event Intervention B, N of Any Adverse Event (Numerator) Intervention B, N Analyzed for … Any Adverse Event (Denominator) Intervention B, % With Any Adverse Event Intervention C, N of Any Adverse … With Any Adverse Event Intervention D, N of Any Adverse Event (Numberator Intervention D, N Analyzed … A, % With Serious Adverse Event Intervention B, N of Serious Adverse Event (Numerator) Intervention … ) Intervention C, % With Serious Adverse Event Intervention D, N of Serious Adverse Event (Numerator)

60. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
    January 01, 2022 - Any Adverse Event Intervention B, N of Any Adverse Event (Numerator) Intervention B, N Analyzed for … Any Adverse Event (Denominator) Intervention B, % With Any Adverse Event Intervention C, N of Any Adverse … With Any Adverse Event Intervention D, N of Any Adverse Event (Numerator) Intervention D, N Analyzed … A, % With Serious Adverse Event Intervention B, N of Serious Adverse Event (Numerator) Intervention … ) Intervention C, % With Serious Adverse Event Intervention D, N of Serious Adverse Event (Numerator)